The author of the only epidemiological study linking the anti-psychotic drug aripiprazole to gambling disorders was expected to undergo harsh questioning in a deposition set for May 16 in a multidistrict product liability proceeding (In re Abilify (Aripiprazole) Prods. Liab. Litig., 2017 BL 162274, N.D. Fla., 3:16-md-2734, 5/15/17).
Dr. Mahyar Etminan, a retained expert witness for the plaintiffs, was expected to be questioned about the methodology he used for “Risk of Gambling Disorder and Impulse Control Disorder with Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study,” which was published in the Journal of Clinical Psychopharmacology.
The stakes are ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.